In this issue of Cell, Guo et al. report the development of a new exon-skipping, RNA-editing-based therapy for Duchenne muscular dystrophy. The dual mechanism of action through both ADAR-dependent and -independent pathways has the potential to be more effective and require a lower dosing frequency than currently available ASO-based exon-skipping treatments.